February 2, 2021

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

ATTN: Mr. Donald Field Ms. Sonia Bednarowski Ms. Kristin Lochhead Mr. Daniel Gordon

RE: Bolt Biotherapeutics, Inc. Registration Statement on Form S-1 File No. 333-252136

Ladies and Gentlemen:

Bolt Biotherapeutics, Inc. (the "*Registrant*") hereby requests that the Securities and Exchange Commission (the "*Commission*") take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on February 4, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of John McKenna and Sonya Erickson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Sonya Erickson at (206) 452-8753.

[SIGNATURE PAGE FOLLOWS]

Very truly yours,

BOLT BIOTHERAPEUTICS, INC.

By: /s/ William P. Quinn

Name: William P. Quinn Title: Chief Financial Officer

cc: Randall C. Schatzman, Ph.D., Bolt Biotherapeutics, Inc. John T. McKenna, Cooley LLP
Sonya F. Erickson, Cooley LLP
Julia Stark, Cooley LLP
Colleen E. Badgley, Cooley LLP
Alan F. Denenberg, Davis Polk & Wardwell LLP
Bryan M. Quinn, Davis Polk & Wardwell LLP

[COMPANY SIGNATURE PAGE TO ACCELERATION REQUEST]